SCHEMBL14814904

SCHEMBL14814904

Cc1ccc(N(C)C(=O)c2sc3nnc(S)n3c2-c2ccccc2)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 7/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 2/20 0.43
LMNA P02545 2/20 0.35
TP53 P04637 2/20 0.35
HSD17B1 P14061 4/20 0.34
HSD17B2 P37059 4/20 0.34
HPGD P15428 1/20 0.34
CNR1 P21554 1/20 0.34
DHODH Q02127 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP1A1 P04798 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2E1 P05181 1/20 0.32
CYP2C8 P10632 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2A6 P11509 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP4B1 P13584 1/20 0.32
CYP2B6 P20813 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14814905 0.90 GPBAR1 (0.45) GPBAR1CYP3A4CYP2C19LMNATP53
SCHEMBL14814884 0.81 GPBAR1 (0.44) GPBAR1CYP3A4CYP2C19LMNATP53
SCHEMBL14833190 0.77 MAPT (0.40) LMNATP53HPGD
SCHEMBL14814566 0.72 DHODH (0.51) GPBAR1CYP3A4CYP2C19LMNADHODH
SCHEMBL14830237 0.69 DHODH (0.49) GPBAR1CYP3A4CYP2C19LMNADHODH
SCHEMBL11006800 0.65 SMN1; SMN2 (0.53) GPBAR1CYP3A4CYP2C19TP53SMN1; SMN2
SCHEMBL14814993 0.64 DHODH (0.47) GPBAR1CYP3A4CYP2C19LMNADHODH
SCHEMBL10940226 0.64 SMN1; SMN2 (0.48) GPBAR1CYP3A4CYP2C19HPGDSMN1; SMN2
SCHEMBL14833280 0.63 DHODH (0.45) GPBAR1CYP3A4CYP2C19LMNADHODH
SCHEMBL30407844 0.61 L3MBTL1 (0.52) GPBAR1CYP3A4CYP2C19LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES SMITH EMILIE D (US) 2013-04-04 US disclosed
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES SMITH EMILIE D (US) 2013-04-04 US disclosed
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES SMITH EMILIE D (US) 2013-04-04 US disclosed
WO-2013049585-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES HENGRUI (USA), LTD. (US) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085157-A1 ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES TGM2, CCT5, TSHR GPBAR1 42/4885CYP3A4 1878/4885CYP2C19 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.